Paradigm Biopharmaceuticals Limited Stock Net Income
| PBIGF Stock | USD 0.23 0.00 0.00% |
Fundamental analysis of Paradigm Biopharmaceutica allows traders to better anticipate movements in Paradigm Biopharmaceutica's stock price by examining its financial health and performance throughout various phases of its business cycle.
Paradigm |
Paradigm Biopharmaceuticals Limited Company Net Income Analysis
Paradigm Biopharmaceutica's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Paradigm Biopharmaceutica Net Income | (39.25 M) |
Most of Paradigm Biopharmaceutica's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Paradigm Biopharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Paradigm Biopharmaceuticals Limited reported net income of (39.25 Million). This is 111.5% lower than that of the Healthcare sector and 156.03% lower than that of the Biotechnology industry. The net income for all United States stocks is 106.87% higher than that of the company.
Paradigm Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Paradigm Biopharmaceutica's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Paradigm Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Paradigm Biopharmaceutica by comparing valuation metrics of similar companies.Paradigm Biopharmaceutica is currently under evaluation in net income category among its peers.
Paradigm Fundamentals
| Return On Equity | -0.65 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | (604.99) % | |||
| Current Valuation | 217 M | |||
| Shares Outstanding | 282.24 M | |||
| Shares Owned By Insiders | 16.46 % | |||
| Shares Owned By Institutions | 18.70 % | |||
| Price To Book | 8.76 X | |||
| Price To Sales | 3,287 X | |||
| Revenue | 79.22 K | |||
| Gross Profit | (64.53 K) | |||
| EBITDA | (39.16 M) | |||
| Net Income | (39.25 M) | |||
| Cash And Equivalents | 39.72 M | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 616.67 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 6.02 X | |||
| Book Value Per Share | 0.18 X | |||
| Cash Flow From Operations | (32.21 M) | |||
| Earnings Per Share | (0.14) X | |||
| Number Of Employees | 16 | |||
| Beta | 1.12 | |||
| Market Capitalization | 347.15 M | |||
| Total Asset | 50.69 M | |||
| Net Asset | 50.69 M |
About Paradigm Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Paradigm Biopharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paradigm Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paradigm Biopharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Paradigm Pink Sheet
Paradigm Biopharmaceutica financial ratios help investors to determine whether Paradigm Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Paradigm with respect to the benefits of owning Paradigm Biopharmaceutica security.